STOCK TITAN

SCYNEXIS (SCYX) CEO awarded 391,333 RSUs, boosting stake to 1.24M shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SCYNEXIS Inc. reported an equity award to its CEO, David Angulo Gonzalez. On January 29, 2026, he received 391,333 shares of common stock as a stock-based grant priced at $0 per share, structured as restricted stock units.

After this award, he beneficially owned 1,244,431 shares of SCYNEXIS common stock in total. The restricted stock units vest in three equal annual installments, with vesting measured from February 28, 2026, which ties the award to multi‑year service and performance with the company.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Angulo Gonzalez David

(Last) (First) (Middle)
1 EVERTRUST PLAZA
13TH FLOOR

(Street)
JERSEY CITY NJ 07302

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SCYNEXIS INC [ SCYX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/29/2026 A 391,333(1) A $0 1,244,431 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents restricted stock units that vest one third per year over three years as measured from February 28, 2026.
/s/ Robert F. Joyce Jr., by Power of Attorney 02/02/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SCYNEXIS (SCYX) disclose about its CEO’s recent equity award?

SCYNEXIS disclosed that CEO David Angulo Gonzalez received 391,333 restricted stock units of common stock at $0 per share. This increases his beneficial ownership to 1,244,431 shares, aligning his compensation with the company’s future performance over several years.

How many SCYNEXIS (SCYX) shares does the CEO own after this Form 4?

After the reported grant, SCYNEXIS CEO David Angulo Gonzalez beneficially owns 1,244,431 shares of common stock. This total includes 391,333 newly awarded restricted stock units that will vest over time, linking a substantial part of his compensation to longer-term company results.

What is the size and nature of the SCYNEXIS (SCYX) CEO’s new grant?

The CEO of SCYNEXIS received 391,333 restricted stock units of common stock for $0 per share. Restricted stock units are stock-based awards that convert into shares over time, encouraging retention and aligning executive incentives with shareholder interests as vesting milestones are met.

When do the SCYNEXIS (SCYX) CEO’s restricted stock units start vesting?

The restricted stock units granted to the SCYNEXIS CEO vest over three years, measured from February 28, 2026. One-third of the units vest each year, creating a staggered schedule that rewards continued service and sustained performance over the full vesting period.

Is the SCYNEXIS (SCYX) CEO’s Form 4 transaction a purchase or an award?

The Form 4 transaction reflects an equity award, not an open-market purchase. The CEO received 391,333 restricted stock units at $0 per share as part of his compensation, increasing his beneficial holdings without cash changing hands for the reported shares.

What does the vesting schedule mean for SCYNEXIS (SCYX) shareholders?

The three-year vesting schedule means the CEO gains full rights to the 391,333 restricted stock units gradually. This structure encourages leadership stability and longer-term decision-making, as a meaningful portion of executive compensation depends on staying with SCYNEXIS through future vesting dates.
Scynexis

NASDAQ:SCYX

SCYX Rankings

SCYX Latest News

SCYX Latest SEC Filings

SCYX Stock Data

31.10M
41.06M
2.09%
26.58%
1.18%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
JERSEY CITY